These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Zoccali C; Bode-Böger S; Mallamaci F; Benedetto F; Tripepi G; Malatino L; Cataliotti A; Bellanuova I; Fermo I; Frölich J; Böger R Lancet; 2001 Dec 22-29; 358(9299):2113-7. PubMed ID: 11784625 [TBL] [Abstract][Full Text] [Related]
26. Asymmetric dimethylarginine, cortisol/cortisone ratio, and C-peptide: markers for diabetes and cardiovascular risk? Anderson JL; Carlquist JF; Roberts WL; Horne BD; May HT; Schwarz EL; Pasquali M; Nielson R; Kushnir MM; Rockwood AL; Bair TL; Muhlestein JB; Am Heart J; 2007 Jan; 153(1):67-73. PubMed ID: 17174641 [TBL] [Abstract][Full Text] [Related]
27. A novel predictor of restenosis and adverse cardiac events: asymmetric dimethylarginine. Ari H; Ari S; Erdoğan E; Tiryakioğlu O; Ustündağ Y; Huysal K; Koca V; Bozat T Heart Vessels; 2010 Jan; 25(1):19-26. PubMed ID: 20091394 [TBL] [Abstract][Full Text] [Related]
28. Plasma ADMA, urinary ADMA excretion, and late mortality in renal transplant recipients. Said MY; Bollenbach A; Minović I; van Londen M; Frenay AR; de Borst MH; van den Berg E; Kayacelebi AA; Tsikas D; van Goor H; Navis G; Bakker SJL Amino Acids; 2019 Jun; 51(6):913-927. PubMed ID: 30915571 [TBL] [Abstract][Full Text] [Related]
29. Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study). Meinitzer A; Seelhorst U; Wellnitz B; Halwachs-Baumann G; Boehm BO; Winkelmann BR; März W Clin Chem; 2007 Feb; 53(2):273-83. PubMed ID: 17185364 [TBL] [Abstract][Full Text] [Related]
30. Association of endothelial dysfunction with cardiovascular risk factors and new-onset diabetes mellitus in patients with hypertension. Triches CB; Mayer S; Quinto BMR; Batista MC; Zanella MT J Clin Hypertens (Greenwich); 2018 May; 20(5):935-941. PubMed ID: 29604155 [TBL] [Abstract][Full Text] [Related]
31. Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Mittermayer F; Krzyzanowska K; Exner M; Mlekusch W; Amighi J; Sabeti S; Minar E; Müller M; Wolzt M; Schillinger M Arterioscler Thromb Vasc Biol; 2006 Nov; 26(11):2536-40. PubMed ID: 16931791 [TBL] [Abstract][Full Text] [Related]
32. Association of Uremic Solutes With Cardiovascular Death in Diabetic Kidney Disease. Sapa H; Gutiérrez OM; Shlipak MG; Katz R; Ix JH; Sarnak MJ; Cushman M; Rhee EP; Kimmel PL; Vasan RS; Schrauben SJ; Feldman HI; Seegmiller JC; Brunengraber H; Hostetter TH; Schelling JR; Am J Kidney Dis; 2022 Oct; 80(4):502-512.e1. PubMed ID: 35351578 [TBL] [Abstract][Full Text] [Related]
33. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. Kistorp C; Raymond I; Pedersen F; Gustafsson F; Faber J; Hildebrandt P JAMA; 2005 Apr; 293(13):1609-16. PubMed ID: 15811980 [TBL] [Abstract][Full Text] [Related]
34. Asymmetric dimethylarginine, related arginine derivatives, and incident atrial fibrillation. Schnabel RB; Maas R; Wang N; Yin X; Larson MG; Levy D; Ellinor PT; Lubitz SA; McManus DD; Magnani JW; Atzler D; Böger RH; Schwedhelm E; Vasan RS; Benjamin EJ Am Heart J; 2016 Jun; 176():100-6. PubMed ID: 27264226 [TBL] [Abstract][Full Text] [Related]
35. Arginine, dimethylated arginine and homoarginine in relation to cardiovascular risk in patients with moderate chronic kidney disease. Hov GG; Aasarød KI; Sagen E; Åsberg A Clin Biochem; 2015 Jul; 48(10-11):646-51. PubMed ID: 25828044 [TBL] [Abstract][Full Text] [Related]
36. Association of urine and plasma ADMA with atherosclerotic risk in DKD cardiovascular disease risk in diabetic kidney disease: findings from the Chronic Renal Insufficiency Cohort (CRIC) study. Schrauben SJ; Sapa H; Xie D; Zhang X; Anderson AH; Shlipak MG; Hsu CY; Shafi T; Mehta R; Bhat Z; Brown J; Charleston J; Chen J; He J; Ix JH; Rao P; Townsend R; Kimmel PL; Vasan RS; Feldman HI; Seegmiller JC; Brunengraber H; Hostetter TH; Schelling JR; Nephrol Dial Transplant; 2023 Nov; 38(12):2809-2815. PubMed ID: 37230949 [TBL] [Abstract][Full Text] [Related]
37. Asymmetric dimethylarginine predicts appropriate implantable cardioverter-defibrillator intervention in patients with left ventricular dysfunction. Lehmann HI; Goette A; Martens-Lobenhoffer J; Hammwöhner M; Röhl FW; Bukowska A; Ghanem A; Klein HU; Bode-Böger SM Europace; 2011 Oct; 13(10):1428-35. PubMed ID: 21752828 [TBL] [Abstract][Full Text] [Related]
38. Higher serum asymmetric dimethylarginine is related to higher risk of heart failure in the EPIC-Potsdam study. Wirth J; Atzler D; di Giuseppe R; Cordts K; Menzel J; Böger RH; Boeing H; Weikert C; Schwedhelm E Amino Acids; 2017 Jan; 49(1):173-182. PubMed ID: 27796501 [TBL] [Abstract][Full Text] [Related]
39. Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuria. Zobel EH; von Scholten BJ; Reinhard H; Persson F; Teerlink T; Hansen TW; Parving HH; Jacobsen PK; Rossing P Cardiovasc Diabetol; 2017 Jul; 16(1):88. PubMed ID: 28697799 [TBL] [Abstract][Full Text] [Related]
40. Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients. Tripepi G; Mattace Raso F; Sijbrands E; Seck MS; Maas R; Boger R; Witteman J; Rapisarda F; Malatino L; Mallamaci F; Zoccali C Clin J Am Soc Nephrol; 2011 Jul; 6(7):1714-21. PubMed ID: 21642364 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]